CoChat

Effects of evolocumab in individuals with type 2 diabetes with and without atherogenic dyslipidemia: An analysis from BANTING and BERSON

Open access
Lorenzatti, Alberto J., Monsalvo, Maria Laura, López, J. Antonio G., Wang, Huei, Rosenson, Robert S. · 2021 · Cardiovascular Diabetology

The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.

Abstract

Background: Atherogenic dyslipidemia (AD), characterized by increased concentrations of apolipoprotein B (ApoB)-containing particles, is often present in individuals with type 2 diabetes mellitus (T2DM). Non-high-density lipoprotein cholesterol (non-HDL-C), cholesterol transported by apolipoprotein B (ApoB)-containing particles), and total apoB are considered secondary goals of lipid-lowering therapy to guide treatment of residual cardiovascular risk. The BANTING and BERSON studies demonstrated that evolocumab added to statin therapy reduced atherogenic lipid and lipoproteins concentrations in patients with T2DM. Methods: This post-hoc analysis combined data from two randomized, placebo-controlled trials, BANTING and BERSON, to investigate the effect of evolocumab (140 mg every two weeks [Q2W] or 420 mg monthly [QM]) on atherogenic lipid (LDL-C, non-HDL-C, VLDL-C, remnant cholesterol) and lipoproteins (ApoB, lipoprotein(a) (Lp[a])), and achievement of 2019 European Society of Cardiology/European Atherosclerosis Society lipid treatment goals in individuals with and without AD. Results: In individuals with high TGs with (n = 389) and without (n = 196) AD receiving background statin therapy, evolocumab, compared with placebo, substantially reduced the cholesterol levels from all ApoB atherogenic lipoproteins (least squares (LS) mean LDL-C by 66.7% to 74.3%, non-HDL-C by 53.4% to 65.8%, median remnant cholesterol by 28.9% to 34.2%, VLDL-C by 16.1% to 19.6%) and median TGs levels (by 17.5% to 19.6%) at the mean of weeks 10 and 12. LS mean ApoB was significantly reduced by 41.5% to 56.6% at week 12. Results were consistent in diabetic individuals with normal TGs (n = 519). Evolocumab was also associated with a significant reduction in median Lp(a) by 35.0% to 53.9% at the mean of weeks 10 and 12. A majority (74.7% to 79.8%) of evolocumab-treated individuals achieved the goal of both an LDL-C < 1.4 mmol/L and an LDL-C reduction of at least 50%, > 75% achieved non-HDL-C < 2.2 mmol/L at the mean of weeks 10 and 12, and > 67% achieved ApoB < 65 mg/dL at week 12. Conclusions: Evolocumab effectively reduced LDL-C, non-HDL-C, ApoB, Lp(a), and remnant cholesterol in individuals with T2DM with and without AD. Evolocumab Q2W or QM enabled most individuals at high/very-high cardiovascular disease risk to achieve their LDL-C, non-HDL-C, and ApoB recommended goals.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s12933-021-01287-6

Cites

48 of 48 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Percentage change from baseline in ApoB and ApoB-lipoprotein cholesterol with evolocumab vs placebo on background statin therapy. Values shown are means of weeks 10 and 12 except for ApoB, which was measured at week 12. All treatment differences between evolocumab and placebo are statistically significant at P < 0.0001. When the calculated LDL-C was < 1.0 mmol/L or TGs were > 4.5 mmol/L, calculated LDL-C was replaced with ultracentrifugation to inform LDL-C and VLDL-C from the same blood sample, if available. ApoB apolipoprotein B, HDL-C high-density lipoprotein cholesterol, LDL-C low-density lipoprotein cholesterol, Lp(a) lipoprotein(a), non-HDL-C non-high-density lipoprotein cholesterol, Q2W every 2 weeks, QM monthly, TG triglycerides, VLDL-C very low-density lipoprotein cholesterol
Fig. 1 Percentage change from baseline in ApoB and ApoB-lipoprotein cholesterol with evolocumab vs placebo on background statin therapy. Values shown are means of weeks 10 and 12 except for ApoB, which was measured at week 12. All treatment differences between evolocumab and placebo are statistically significant at P < 0.0001. When the calculated LDL-C was < 1.0 mmol/L or TGs were > 4.5 mmol/L, calculated LDL-C was replaced with ultracentrifugation to inform LDL-C and VLDL-C from the same blood sample, if available. ApoB apolipoprotein B, HDL-C high-density lipoprotein cholesterol, LDL-C low-density lipoprotein cholesterol, Lp(a) lipoprotein(a), non-HDL-C non-high-density lipoprotein cholesterol, Q2W every 2 weeks, QM monthly, TG triglycerides, VLDL-C very low-density lipoprotein cholesterolCC BY · PubMed Central
Fig. 2 Percentage change from baseline in VLDL-C, remnant cholesterol and TGs with evolocumab vs placebo in participants with high TGs with or without AD on background statin therapy. All treatment differences between evolocumab and placebo are statistically significant at P < 0.0001 except for VLDL-C in the group with high TGs and normal HDL-C (P = 0.0002). HDL-C high-density lipoprotein cholesterol, TG triglycerides, VLDL-C very low-density lipoprotein cholesterol
Fig. 2 Percentage change from baseline in VLDL-C, remnant cholesterol and TGs with evolocumab vs placebo in participants with high TGs with or without AD on background statin therapy. All treatment differences between evolocumab and placebo are statistically significant at P < 0.0001 except for VLDL-C in the group with high TGs and normal HDL-C (P = 0.0002). HDL-C high-density lipoprotein cholesterol, TG triglycerides, VLDL-C very low-density lipoprotein cholesterolCC BY · PubMed Central
Fig. 3 Correlation of changes in ApoB100 with non-HDL-C, remnant cholesterol and TGs. The X axis represents changes in ApoB100 from baseline to the mean of weeks 10 and 12 in evolocumab-treated patients; the Y axis represents changes in non-HDL-C, TGs or remnant cholesterol from baseline to the mean of weeks 10 and 12 in evolocumab-treated patients. All correlation coefficients are statistically significant at P < 0.0001. ApoB apolipoprotein B, HDL-C high-density lipoprotein cholesterol, LDL-C low-density lipoprotein cholesterol, non-HDL-C non-high-density lipoprotein cholesterol, TG triglycerides
Fig. 3 Correlation of changes in ApoB100 with non-HDL-C, remnant cholesterol and TGs. The X axis represents changes in ApoB100 from baseline to the mean of weeks 10 and 12 in evolocumab-treated patients; the Y axis represents changes in non-HDL-C, TGs or remnant cholesterol from baseline to the mean of weeks 10 and 12 in evolocumab-treated patients. All correlation coefficients are statistically significant at P < 0.0001. ApoB apolipoprotein B, HDL-C high-density lipoprotein cholesterol, LDL-C low-density lipoprotein cholesterol, non-HDL-C non-high-density lipoprotein cholesterol, TG triglyceridesCC BY · PubMed Central
Fig. 4 Percentage of participants who achieved each lipid treatment goal with evolocumab vs placebo on background statin therapy. Values shown are means of weeks 10 and 12 except for ApoB, which was measured at week 12. The treatment differences between evolocumab and placebo for all endpoints are statistically significant at P < 0.0001 based on Cochran-Mantel–Haenszel tests stratified by study. When the calculated LDL-C was < 1.0 mmol/L or TGs were > 4.5 mmol/L, calculated LDL-C was replaced with ultracentrifugation to inform LDL-C and VLDL-C from the same blood sample, if available. ApoB apolipoprotein B, BL baseline, LDL-C low-density lipoprotein cholesterol, non-HDL-C non-high-density lipoprotein cholesterol, Q2W every 2 weeks, QM monthly, TGs triglycerides
Fig. 4 Percentage of participants who achieved each lipid treatment goal with evolocumab vs placebo on background statin therapy. Values shown are means of weeks 10 and 12 except for ApoB, which was measured at week 12. The treatment differences between evolocumab and placebo for all endpoints are statistically significant at P < 0.0001 based on Cochran-Mantel–Haenszel tests stratified by study. When the calculated LDL-C was < 1.0 mmol/L or TGs were > 4.5 mmol/L, calculated LDL-C was replaced with ultracentrifugation to inform LDL-C and VLDL-C from the same blood sample, if available. ApoB apolipoprotein B, BL baseline, LDL-C low-density lipoprotein cholesterol, non-HDL-C non-high-density lipoprotein cholesterol, Q2W every 2 weeks, QM monthly, TGs triglyceridesCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 48 references

Cited by

See all 35

Metadata

Authors
Lorenzatti, A. J., Monsalvo, M. L., López, J. A. G., Wang, H., & Rosenson, R. S.
Affiliations
  • Instituto Médico DAMIC (AR)
  • Amgen (United States) (US)
  • Icahn School of Medicine at Mount Sinai (US)
Corresponding author
Lorenzatti, Alberto J.
Venue
Cardiovascular Diabetology
Published
2021-04-30
Volume
20
Issue
1
Pages
94-94
ISSN
1475-2840 (ISSN-L)
OpenAlex
W3158914372
Cited by
34
References
48
Citations by year
2026: 3 · 2025: 5 · 2024: 4 · 2023: 10 · 2022: 10 · 2021: 2
FWCI
6.34
Type
journal article
Language
en
Open access
Licence
Locations
  • Cardiovascular Diabetology (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
Amgen
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
Keywords
evolocumab, type 2 diabetes, atherogenic dyslipidemia, apolipoprotein B, non-HDL cholesterol, remnant cholesterol, lipoprotein(a), triglycerides, LDL cholesterol, VLDL cholesterol, PCSK9 inhibition, statin therapy, cardiovascular risk
MeSH terms
Proprotein Convertase 9, PCSK9 Inhibitors, Aged, Anticholesteremic Agents, Cholesterol, Diabetes Mellitus, Type 2, Drug Therapy, Combination, Female, Humans, Lipids, Male, Middle Aged, Time Factors, Triglycerides, Biomarkers, Randomized Controlled Trials as Topic, Treatment Outcome, Clinical Trials, Phase III as Topic, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Dyslipidemias, Apolipoprotein B-100, Antibodies, Monoclonal, Humanized

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effects of evolocumab in individuals with type 2 diabetes with and without atherogenic dyslipidemia: An analysis from BANTING and BERSON. https://app.cochat.ai/papers/10.1186/s12933-021-01287-6
The paper
Lorenzatti, A. J., Monsalvo, M. L., López, J. A. G., Wang, H., & Rosenson, R. S. (2021). Effects of evolocumab in individuals with type 2 diabetes with and without atherogenic dyslipidemia: An analysis from BANTING and BERSON. Cardiovascular Diabetology. https://doi.org/10.1186/s12933-021-01287-6

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.